Chinese
English
描述
Multi-Omics for Drug Development
What is Multi-Omics?
Multi-omics provides a comprehensive view of biological systems, enabling researchers to explore complex biological mechanisms and uncover novel insights across multiple biological levels. By integrating genomic data with transcriptomic, epigenomic, and proteomic data, multi-omics analysis offers a deeper understanding of gene expression, molecular regulation, and protein changes.This integrated approach helps reveal how molecular alterations influence normal development, cellular responses, and disease progression. By bridging genotypes and phenotypes, multi-omics technologies empower researchers to identify novel therapeutic targets and biomarkers, accelerating discoveries in biomedical research and drug development.
Services
  • Immune checkpoint inhibitors (ICIs) are among the most established and widely used therapeutic strategies in cancer immunotherapy. The major immune checkpoint molecules associated with tumors include PD-1, PD-L1, and CTLA-4. Clinical studies of PD-1/PD-L1 inhibitors have demonstrated that treatment response is associated with biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI).
    Tumor
    Immune checkpoint inhibitors (ICIs) are among the most established and widely used therapeutic strategies in cancer immunotherapy. The major immune checkpoint molecules associated with tumors include PD-1, PD-L1, and CTLA-4. Clinical studies of PD-1/PD-L1 inhibitors have demonstrated that treatment response is associated with biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI).
  • The testing solutions and customized services provided by Sequanta meet the requirements for IND/NDA applications and the quality standards for clinical trials. Sequanta has collaborated with leading industry partners to support multiple IND/NDA submissions, clinical trial projects, and thousands of clinical sample tests.
    Cell and Gene Therapy
    The testing solutions and customized services provided by Sequanta meet the requirements for IND/NDA applications and the quality standards for clinical trials. Sequanta has collaborated with leading industry partners to support multiple IND/NDA submissions, clinical trial projects, and thousands of clinical sample tests.
  • Sequanta provides professional medical genetic interpretation services based on the latest scientific evidence, supported by independently developed and validated variant interpretation software and standardized analysis workflows. These capabilities improve the accuracy of variant interpretation and classification, providing comprehensive, precise, and scientifically supported guidance for molecular diagnosis of diseases.
    Solutions for Genetic Disorder
    Sequanta provides professional medical genetic interpretation services based on the latest scientific evidence, supported by independently developed and validated variant interpretation software and standardized analysis workflows. These capabilities improve the accuracy of variant interpretation and classification, providing comprehensive, precise, and scientifically supported guidance for molecular diagnosis of diseases.
  • PDX models are valuable tools for drug discovery and development, enabling researchers to evaluate therapeutic strategies and gain deeper insights into disease mechanisms. Sequanta provides precise, efficient, and high-throughput testing solutions for preclinical drug research based on PDX models. Through multidimensional drug target exploration, evaluation of drug efficacy and immune response mechanisms, high-throughput drug screening, and enhanced quality control throughout experimental and production processes, Sequanta accelerates more precise and efficient innovative drug development.
    Solutions for PDX models
    PDX models are valuable tools for drug discovery and development, enabling researchers to evaluate therapeutic strategies and gain deeper insights into disease mechanisms. Sequanta provides precise, efficient, and high-throughput testing solutions for preclinical drug research based on PDX models. Through multidimensional drug target exploration, evaluation of drug efficacy and immune response mechanisms, high-throughput drug screening, and enhanced quality control throughout experimental and production processes, Sequanta accelerates more precise and efficient innovative drug development.
  • Leveraging multi-omics technologies, including genomics, transcriptomics, and proteomics, Sequanta provides innovative and comprehensive solutions for vaccine research and development. Our integrated platform supports metagenomic sequencing, plasma biomarker screening, and immune profiling to help pharmaceutical companies accelerate vaccine development.
    Solutions for Vaccine
    Leveraging multi-omics technologies, including genomics, transcriptomics, and proteomics, Sequanta provides innovative and comprehensive solutions for vaccine research and development. Our integrated platform supports metagenomic sequencing, plasma biomarker screening, and immune profiling to help pharmaceutical companies accelerate vaccine development.
  • By integrating genomic, transcriptomic, proteomic, single-cell omics, and spatial multi-omics data, AI algorithms help overcome the limitations of traditional statistical approaches, enabling a transition from “data accumulation” to “knowledge discovery.” In tumor immune microenvironment analysis, AI enables precise identification of therapeutic response biomarkers; in mRNA vaccine development, it facilitates dynamic tracking of clonal immune responses; and in proteomic profiling, it supports the development of high-dimensional predictive models.
    Solutions for Full-Stack AI Multi-Omics
    By integrating genomic, transcriptomic, proteomic, single-cell omics, and spatial multi-omics data, AI algorithms help overcome the limitations of traditional statistical approaches, enabling a transition from “data accumulation” to “knowledge discovery.” In tumor immune microenvironment analysis, AI enables precise identification of therapeutic response biomarkers; in mRNA vaccine development, it facilitates dynamic tracking of clonal immune responses; and in proteomic profiling, it supports the development of high-dimensional predictive models.
Contact us
240 Hedan Road, Waigaoqiao Pilot Free Trade Zone, Shanghai, China
Shanghai International Biomedical Science & Innovation Center info@sequanta.com
021-20500599
Copyright: Shanghai Sequanta Technologies Co., Ltd. Record No.: Shanghai
ICP Record No. 2021028059-1